Feymer(SH:688350)2025-04-02 12:45Financial Performance - The company reported a net profit attributable to shareholders of the listed company for 2024 as negative, thus not meeting the conditions for cash dividends as per the company's articles of association[6]. - The company's operating revenue for 2024 was CNY 1,565,594,552.20, a decrease of 4.54% compared to the previous year[22]. - The net profit attributable to shareholders was CNY -4,654,517.15, marking a significant decline from a profit of CNY 27,207,614.93 in 2023[25]. - The basic earnings per share for 2024 was CNY -0.04, down from CNY 0.22 in 2023[24]. - The company's main business revenue decreased by 5.33% to 1.538 billion RMB, while the main business cost decreased by 3.70% to 1.337 billion RMB[125]. - The gross profit margin for the main business was 13.07%, reflecting a decline[125]. - The company faced intensified competition in the functional monomer sector, impacting market share and profitability[119]. - The company reported a significant increase in financial expenses due to convertible bond interest expenses[123]. Shareholder Actions - The company plans not to distribute profits for the 2024 fiscal year, considering the current industry situation and operational needs[6]. - The company has not implemented any capital reserve transfer to increase share capital or other forms of distribution for 2024[6]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not faced significant adverse impacts from industry competition or related party transactions[188]. Risk Management - The company has detailed various risks and countermeasures in the report, urging investors to pay attention to investment risks[4]. - The company is exposed to environmental risks due to stricter regulations and potential penalties if it fails to meet new standards[111]. - The company faces risks related to significant performance declines due to macroeconomic fluctuations and changes in downstream industries[107]. - The company is at risk of core technology personnel loss due to intense competition for high-end talent in the industry[109]. Research and Development - The company achieved a total R&D investment of ¥73,341,502.97, a decrease of 4.95% compared to the previous year[89]. - R&D investment accounted for 4.68% of total revenue, a slight decrease of 0.02 percentage points from the previous year[89]. - The company added 52 new authorized patents during the reporting period, including 21 invention patents, bringing the total to 290 authorized patents[38]. - The company has developed 22 core technologies in functional monomer manufacturing, water-soluble polymer production, and membrane technology, with several patents granted for these innovations[78]. Market Expansion - The company is actively expanding its overseas business to mitigate domestic market challenges[24]. - The international business department reported a growth of 7.91% in foreign sales, despite challenges from international market conditions[35]. - The company is focusing on expanding its investment in the chemical new materials sector, particularly in electronic materials and bio-chemical materials, to enhance market competitiveness[156]. - The company is committed to expanding its international market presence, particularly in Southeast Asia and the Middle East, to increase its overseas business share[170]. Operational Efficiency - The net cash flow from operating activities increased by 14.60% to CNY 117,376,548.90, primarily due to a reduction in tax payments[25]. - The company has deployed various digital systems, including LIMS and WMS, to enhance operational efficiency and data management across R&D, production, and supply chain[42]. - The company is implementing a digital transformation strategy to enhance operational efficiency and customer satisfaction through data-driven insights and innovative product development[74]. - The company is leveraging digital transformation to improve operational efficiency and cost control through lean management practices[171]. Governance and Compliance - The company has established a comprehensive governance structure, including a shareholders' meeting, board of directors, supervisory board, and management[178]. - The company strictly adheres to the requirements of the China Securities Regulatory Commission and the stock exchange for listed companies, enhancing governance and internal control management[175]. - The company emphasizes investor relations, actively communicating with shareholders and addressing their concerns to protect minority shareholders' rights[184]. - The company conducted its annual shareholders' meeting and four extraordinary meetings, ensuring fair treatment of all investors[178]. Product Development - The company is focusing on developing green and efficient sludge treatment agents to meet the national requirements for sludge treatment, which emphasizes reduction, stabilization, harmlessness, and resource utilization[69]. - The company is actively pursuing external collaborations, particularly in "industry-university-research" partnerships, to enhance its research and development capabilities[53]. - The company is focusing on MBR technology for municipal and industrial wastewater treatment, with 1 invention patent and 7 utility model patents aimed at meeting stringent discharge requirements[80]. - The company is enhancing its market share through the release of production capacity from fundraising projects and the construction of a production base in Anhui[66].